SWOG clinical trial number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.

Open
Phase
Accrual
17%
Abbreviated Title
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for,…
Status Notes
Arm 2 will be Permanently Closed to Accrual and Arms 1 & 3 will be Reopened to Accrual as of 02/15/2024, 12 PM PST.
Activated
02/16/2021
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Genitourinary Cancer

Treatment

Gemcitabine hydrochloride Eribulin mesylate

Eligibility Criteria Expand/Collapse

5.1 Disease Related Criteria

a. Participant must have predominant histologically and cytologically proven urothelial carcinoma in a metastatic site.

b. Participant must have evidence of metastatic urothelial carcinoma based on CT or MRI within 28 days prior to registration.

c. Participant must have had progression of disease following prior therapy at the discretion of the treating investigator.

d. Participants must not require immediate CNS-specific treatment, in the opinion of the treating investigator if they have active brain metastases (defined as new or progressive brain metastases) or leptomeningeal disease.

5.2 Prior/Concurrent Therapy Criteria

a. Participant must have had prior systemic therapy in metastatic setting that:

I. Included enfortumab vedotin

II. Included a PD1/PDL1 antibody

NOTE: Under the discretion of the treating physician, participants who are not candidates for PD1/PDL1 antibody systemic therapy are allowed.

b. Participant must have completed any planned surgery or radiation therapy prior to registration.

c. Participant must not have unresolved toxicities from prior surgeries or radiation therapy > Grade 1 at the time of registration.

5.3 Clinical/Laboratory Criteria

a. Participant must be ≥ 18 years of age.

b. Participant must have Zubrod Performance Status 0-2 (see Section 10.0).

c. Participant must have history and physical examination within 28 days prior to registration.

d. Participant must have complete blood count (CBC), complete metabolic panel including liver function tests, and LDH obtained within 28 days prior to registration.

e. Participant must have adequate kidney function as evidenced by measured or calculated creatinine clearance ≥ 20 mL/min within 28 days prior to registration.

Calculated creatinine clearance = (140 - age) x wt (kg) x 0.85 (if female)
72 x creatinine (mg/dl)

f. Participant must have adequate hepatic function documented by either AST or ALT ≤ 3 x IULN within 28 days prior to registration. If both AST and ALT are performed, both must be ≤ 3 x IULN. For participants with liver metastases, AST or ALT must be ≤ 5 x IULN.

g. Participant must be on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration if they are known to have human immunodeficiency virus (HIV)-infection.

h. Participants must have undetectable HBV viral load within 28 days prior to registration if participant has known chronic hepatitis B virus (HBV) infection.

i. Participants with a known history of hepatitis C virus (HCV) infection must have an undetectable HCV viral load within 28 days prior to registration.

j. Participants may have a prior or concurrent malignancy provided the natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen per the opinion of the treating investigator.

k. Participants must not be planning to take strong or moderate CYP3A or CYP2C8 inhibitors or inducers if randomized to Arm 1 and SOC regimen chosen is Paclitaxel or Docetaxel. Participants receiving strong or moderate CYP3A or CYP2C8 inducers must discontinue use at least 2 weeks prior to randomization.

l. Participant must not have a known history of QTc prolongation.

m. Participants must not be pregnant or nursing due to the risk of harm to a fetus or nursing infant. Women and men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study and 6 months (females) or 3.5 months (males) after the last dose.. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.

5.4 Specimen Submission Criteria

a. Participants must be offered the opportunity to participate in specimen banking as outlined in Section 15.1.


5.5 Regulatory Criteria

a. Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

b. As a part of the OPEN registration process (see Section 13.5 for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.


Publication Information Expand/Collapse

2023

A Phase III Randomized Trial of Eribulin (E) with or without gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClicalTrials.gov NCT04579224)

S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;I Thompson J Clin Oncol 41, 2023 (suppl 6; abstr TPS581); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;I Thompson J Clin Oncol 41, 2023 (suppl 16; abstr TPS4608); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tips, poster

2022

A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClinicalTrials.gov NCT04579224)

S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;IM Thompson J Clin Oncol 40, 2022 (suppl 16; abstr TPS4608), poster 94a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/A031901